← Back to Clinical Trials
Recruiting NCT06679205

NCT06679205 Effectiveness of a Multidisciplinary Treatment for Patients With Chronic Low Back Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06679205
Status Recruiting
Phase
Sponsor University of Barcelona
Condition Chronic Low-back Pain (cLBP)
Study Type INTERVENTIONAL
Enrollment 62 participants
Start Date 2025-01-14
Primary Completion 2026-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Multidisciplinary and multimodal interventionUsual Care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 62 participants in total. It began in 2025-01-14 with a primary completion date of 2026-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

PAINDOC is a treatment program that includes 4 disciplines that, separately, have demonstrated their effectiveness in the treatment of chronic low back pain: education in pain neuroscience, therapeutic education (Empowered Relief®), psychotherapy based on cognitive-behavioral therapy and therapeutic exercise. The primary objective of the study is to evaluate the effectiveness of the PAINDOC multidisciplinary treatment program in reducing pain intensity and improving quality of life in persons with chronic low back pain referred to the pain unit of the Hospital Clinic of Barcelona, compared to usual care treatment. As secondary objectives, the present study aims to evaluate the effect of the PAINDOC program on: * The reduction of pain-related disability. * The reduction of pain catastrophizing. * The improvement in perceived social support. * The improvement in perceived autonomy (self-efficacy). * The reduction of analgesic, anti-inflammatory and adjuvant analgesic medication. The main questions it aims to answer are: * Is the proposed multidisciplinary treatment effective in improving pain-related outcomes? * Is the proposed multidisciplinary treatment effective in reducing analgesic medication? Participants will receive either usual care (pharmacological control) or the PAINDOC program, which consists of 7 multidisciplinary sessions within 2 months. There will be one therapeutic education session called Empowered Relief®, 2 pain neuroscience education sessions, one pain psychology session and 3 therapeutic education sessions. Besides, participants will be assessed using written questionnaires before treatment, at 3 months and at 6 months. Researchers will assess the effectiveness of the multidisciplinary treatment group comparing both groups to see if there is any difference in several pain-related outcomes.

Eligibility Criteria

Inclusion Criteria: * Patients over 18 years of age. * Patients with primary chronic low back pain (non-specific chronic low back pain) of axial predominance. * Experiencing pain at least 50% of the time over the last 6 months. * Average weekly pain intensity equal or greater than 4 out of 10 on a verbal numerical scale. * Be agreeable to receiving active, non-pharmacological and non-surgical treatment. Exclusion Criteria: * Inflammatory low back pain. * History of cancer in the last 5 years. * Unexplained and unintentional weight loss of 10 Kg or more over the preceding 12-month period. * Lack of control of bowel and bladder function (cauda equina). * Difficulty in performing the sessions due to severe physical disability. * Diagnosis of severe mental illness (schizophrenia, major depression, bipolar disorder, etc.). * Strong prescription opioid or parenteral medication addiction disorders. * Technical-logistical problems (inability to attend treatment sessions or inability to fill out assessment questionnaires). * Problems in understanding the content of the sessions (language barrier, severe hearing loss or severe cognitive impairment). * Have sought compensation or entered into litigation in the preceding 12-month period.

Contact & Investigator

Central Contact

Anna Dalmau-Roig, MD

✉ dalmaur@clinic.cat

📞 +34 639482849

Principal Investigator

Marc Terradas-Monllor, PhD

STUDY DIRECTOR

University of Vic

Frequently Asked Questions

Who can join the NCT06679205 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Low-back Pain (cLBP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06679205 currently recruiting?

Yes, NCT06679205 is actively recruiting participants. Contact the research team at dalmaur@clinic.cat for enrollment information.

Where is the NCT06679205 trial being conducted?

This trial is being conducted at Barcelona, Spain, Barcelona, Spain.

Who is sponsoring the NCT06679205 clinical trial?

NCT06679205 is sponsored by University of Barcelona. The principal investigator is Marc Terradas-Monllor, PhD at University of Vic. The trial plans to enroll 62 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology